This approach has shown potential in lung adenocarcinoma treatments with EGFR-targeting TKIs (176), such as osimertinib, where data from clinical trials (e.g., NEJ002-NCT00322452 and FLAURA-NCT02296125) has been used to align model predictions with actual patient outcomes (177). Here, EGFR is linked to lung adenocarcinoma.